-42%

est. 2Y upside i

Healthcare

Ultrahuman is the world's most comprehensive self-quantification platform. Their products include the Ultrahuman Ring AIR–the world’s lightest sleep-tracking wearable; Ultrahuman M1–a continuous glucose monitoring platform; Ultrahuman Home–a home health device that monitors environmental markers that affect your health every day; and Blood Vision–a preventive blood testing platform.

Rank

#3699

Sector

HealthTech

Est. Liquidity

~1Y

Data Quality

Data: High

Ultrahuman presents a high-risk, moderate-reward equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (25%)+100%

Ultrahuman successfully navigates the Oura patent dispute by redesigning its smart ring for the US market and expanding aggressively into new international markets (Canada, Mexico, Australia). The subscription engine (PowerPlugs, Blood Vision) accelerates, pushing overall revenue to over $300M by 2027, justifying a $1.15B+ valuation at IPO, a 2x from current levels.

Base (30%)+20%

Ultrahuman maintains its strong growth trajectory outside the US and eventually resolves the Oura patent dispute, but market share gains are slower due to increased competition from Samsung and other incumbents. Revenue reaches approximately $180M by 2027, leading to an IPO valuation of around $690M, a modest upside from the current valuation.

Bear (45%)-50%

The US import and sales ban on Ultrahuman's smart rings persists or is not effectively mitigated by redesigns, severely impacting its largest revenue stream (60% of FY25 operating revenue). Intense competition from Oura, WHOOP, and the Samsung Galaxy Ring further erodes market share, leading to stalled growth and a down round or acquisition at a $287.5M valuation, wiping out a significant portion of common stock value.

Est. time to liquidity~1.0 years

Preference Stack Risk

moderate

Investors hold approximately $71M in liquidation preferences. In an exit at or below the current $575M valuation, common shareholders would receive proceeds after this $71M.

Dilution Risk

moderate

The company is reportedly seeking a larger equity funding round of $100-120M, which will cause further dilution for existing shareholders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Ultrahuman's equity.

Questions to Ask at the Interview

Strategic questions based on Ultrahuman's data — designed to show you've done your homework.

  • 1

    “How is Ultrahuman strategically addressing the US import ban on the Ring Air, and what is the timeline and confidence level for a redesigned product to re-enter this critical market?”

  • 2

    “With Samsung entering the smart ring market and Oura being a direct competitor, what specific product differentiation and market penetration strategies will Ultrahuman employ to maintain its growth trajectory and defend its market position over the next 2-3 years?”

  • 3

    “Given the declared IPO plans for 2026 and the ongoing venture debt funding, how does the company envision the path to liquidity for employees, and what are the current expectations regarding further dilution from future equity rounds?”

Community

Valuation Sentiment

Our model estimates -42% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.